-
Domestic innovative drug companies are ushering in an intensive harvest period!
Time of Update: 2022-01-10
In recent years, with the successive release of a series of favorable pharmaceutical innovation policies such as speeding up the review and approval of new drugs, as well as the high R&D investment of local innovative drug companies, the continuous breakthroughs in key technologies have made domestic innovative drug companies usher in an intensive harvest period.
-
A large number of enterprises will benefit from the publication of documents in various places to promote the development of the Chinese medicine industry
Time of Update: 2022-01-10
With the help of these policies, the industry expects that a large number of traditional Chinese medicine companies will usher in a larger market space and move toward a higher-quality development path through continuous inheritance of the essence, integrity and innovation .
-
Merck's oral new crown drug Molnupiravir receives FDA emergency use authorization
Time of Update: 2022-01-10
On December 23, Merck/Ridgeback announced that the oral new crown drug Molnupiravir (MK-4482/EIDD-2801) has received emergency use authorization from the US FDA for the treatment of adult patients with mild to moderate COVID-19 .
-
Junshi Biologics was approved for subcutaneous injection of PD-1
Time of Update: 2022-01-10
Pre-clinical in vivo pharmacodynamic tests have shown that JS001sc has a significant tumor-inhibiting effect in animal models when administered by subcutaneous injection.
3 mg/kg, JS001sc administered by subcutaneous injection and Terry administered by intravenous injection The anti-tumor effect of prilimumab was equivalent, and no significant difference was seen .
-
A large variety of 2 billion heparin!
Time of Update: 2022-01-10
In 2020, the terminal sales of public medical institutions in China will exceed 2 billion yuan, a year-on-year increase of 6.
com, the domestic market for enoxaparin sodium injection has continued to expand in recent years.
-
A large number of medical devices are unqualified in random inspections, and equipment companies need to accelerate the improvement of quality and management systems
Time of Update: 2022-01-10
According to the announcement, the Henan Provincial Drug Administration organized local regulatory agencies to conduct random inspections of medical device products across the province .
-
136 drugs collectively raise prices, the increase is more than 3000%
Time of Update: 2022-01-10
On December 21, the Centralized Procurement Network of Medicines and Medical Consumables in Liaoning Province issued the "Notice on Announcement of the Dynamic Adjustment of Drug Online Prices", which proposed to increase the online prices of 136 drugs .
-
Aurora A Small Molecule Oral Inhibitor Approved for Clinical Trial in China
Time of Update: 2022-01-10
The approved indication is the combination with paclitaxel for the treatment of advanced ovarian cancer, Patients with fallopian tube cancer and primary peritoneal cancer .
The combination of VIC-1911 and paclitaxel has the potential to prolong patient survival and reduce the recurrence rate .
-
The cold wave "frozen" is true, but this pharmaceutical market segment is extremely hot
Time of Update: 2022-01-10
In recent years, with the rapid development of freeze-drying technology and the improvement of GMP requirements in the pharmaceutical industry, the medical freeze-drying machine market has developed rapidly, especially equipment with larger specifications, as well as functional combinations (such as granulation-drying, drying —The demand for filtration equipment continues to increase, and the market prospect of the entire freeze dryer is very broad .
-
Seven batches and eight rounds of national procurement communication meetings were held, and the forecasting rules were adjusted in three aspects
Time of Update: 2022-01-10
Five batches and six rounds of national procurement of chemical medicines, the selection method adopted is based on the price from low to high, the relevant companies take turns to choose the area .
-
New drug application for RTK inhibitor for the treatment of renal cell carcinoma
Time of Update: 2022-01-10
Recently, Allarity Therapeutics announced that it has submitted a New Drug Application (NDA) to the US FDA to seek approval of the receptor tyrosine kinase (RTK) inhibitor dovitinib for the third-line treatment of renal cell carcinoma (RCC) .
-
Another PD-1 drug was approved for clinical use, and the "involution" in this field continues to intensify
Time of Update: 2022-01-10
Recently, Junshi Biological released an announcement stating that the company's application for clinical trial of JS001sc injection was accepted by the China Food and Drug Administration .
-
The rare disease drug market with more than 20 billion U.S. dollars is attracting many pharmaceutical companies to deploy
Time of Update: 2022-01-10
Facing the huge blue ocean of the market, coupled with policies encouraging pharmaceutical companies to develop rare disease drugs, for example, on October 11 this year, the "Technical Guidelines for the Clinical Research and Development of Rare Disease Drugs (Draft for Comment)" was released to improve the clinical research and development of rare diseases.
-
To protect the health of Chinese families, Merck Gehuazhi XR and Kangxin are both on the list of "Chinese Family Standing Medicines"
Time of Update: 2022-01-10
Family stock medicine is the first line of defense to protect family health . On December 23, the 2020-2021 “China Family Standing Medicine Listed Brand” was announced . Merck's classic hypoglycem
-
Luye Pharma grants the exclusive commercialization rights of Kinsey Pharmaceutical Liss' Ming transdermal patch in mainland China
Time of Update: 2022-01-10
According to the agreement, Luye Pharma has granted Jinsai Pharmaceutical the import, sales, promotion, marketing and use of Liss Ming transdermal patch (single-day patch) and Liss Ming transdermal patch (multi-day patch) in mainland China.
-
Bibate Pharmaceutical's CDK4/6 inhibitors are approved for Phase 3 clinical trials
Time of Update: 2022-01-10
ArticleMedicine GuanlanOn December 22, Bibate Pharmaceutical announced that its phase 3 clinical trial application of the CDK4/6 inhibitor BEBT-209 combined with fulvestrant in the treatment of HR+/HER2- advanced breast cancer has been approved by the China National Medical Products Administration.
-
Industry: 2022 may be an important year for Chinese innovative drugs to be launched overseas
Time of Update: 2022-01-10
Recently, the CITIC Construction Investment Research Report pointed out that it continues to be optimistic about the internationalization of leading innovative pharmaceutical companies.
-
Chinese scientists achieve direct measurement of the electrostatic interaction of proteins in cells
Time of Update: 2022-01-10
The researchers used the cell core magnetic resonance technology and the double mutational cycle (double mutational cycle, DMC) method to study the 8 pairs of charge interactions in the intracellular IgG binding protein GB3, and the measurement results were compared with the static electricity measured in the buffer.
-
The pharmaceutical company was fined 300,000 yuan for stepping on the "red line" of the advertisement
Time of Update: 2022-01-10
For example, in August 2020, Yaben Chemical responded to investors’ questions on the interactive platform of the Shenzhen Stock Exchange about whether the company produces pharmaceutical intermediates for antiviral drugs related to the pneumonia epidemic.
-
Conversion of a single oral formulation of dextromethorphan hydrobromide to a prescription drug
Time of Update: 2022-01-10
2. After the supplementary application for the modification of the instructions for this product is approved, the holder of the drug marketing authorization of the relevant product shall replace the instructions and labels of the medicines that have been shipped out of the factory within 9 months, and shall collect and report adverse reaction information in a timely manner.
